STAT

CDC director’s investment in tobacco, drug companies baffles ethics experts

Asked about CDC Director Brenda Fitzgerald's apparent conflicts of interest, one ethicist said: "This is not standard operating practice.”
Source: Branden Camp/AP

It was a financial investment in a tobacco company that helped lead to the downfall of Brenda Fitzgerald, who until Wednesday was the director of the Centers for Disease Control and Prevention.

For many in the public health community, the notion that the head of the CDC held shares of a company in an industry that has been so anathema to the agency’s mission was shocking.

But Fitzgerald also purchased shares in pharma giants Merck and Bayer after

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks